Generic placeholder image

Current Medicinal Chemistry


ISSN (Print): 0929-8673
ISSN (Online): 1875-533X

Review Article

The mTOR/4E-BP1/eIF4E Signalling Pathway as a Source of Cancer Drug Targets

Author(s): Cristina Maracci, Stefano Motta, Alice Romagnoli, Matteo Costantino, Paola Perego* and Daniele Di Marino

Volume 29, Issue 20, 2022

Published on: 01 April, 2022

Page: [3501 - 3529] Pages: 29

DOI: 10.2174/0929867329666220224112042

Price: $65


The mechanistic/mammalian target of rapamycin (mTOR) is the crucial hub of signalling pathways that regulate essential steps in the cell life cycle. Once incorporated in the mTORC1 complex, mTOR phosphorylates the eukaryotic initiation factor 4E (eIF4E)- binding protein 1 (4E-BP1), which then releases eIF4E. When not bound to 4EBPs, eIF4E recognizes the mRNA 5’-cap structure and, together with eIF4A and eIF4G, it forms the eIF4F complex that recruits the ribosome on the mRNA. Under normal conditions, the cellular concentration of eIF4E is very low, making eIF4E the limiting factor in the initiation of protein synthesis. The vast majority of cancer types are characterized by the simultaneous deregulation of the mTOR/4E-BP1 signalling pathway and upregulation of eIF4E, which lead to an increased expression of cancer-promoting genes and deregulated cellular growth. Over the last decades, a growing number of selective inhibitors of the mTOR/4E-BP1/eIF4E pathway have been discovered or designed. Several inhibitors with encouraging preclinical results have been tested in clinical trials. This review summarizes the most recent research on drug development against mTOR, 4E-BP1, and eIF4E, describing the design rationale and the available structural and functional data on the most promising compounds.

Keywords: mTOR allosteric inhibitors, rapamycin, eIF4F, translational control, cancer, PIKKs.

Rights & Permissions Print Cite
© 2024 Bentham Science Publishers | Privacy Policy